Software developer iCAD and image processing specialist TeraRecon have signed a nonexclusive product licensing and distribution agreement under which TeraRecon will develop a new server-based product offering to include iCAD lung cancer detection,
Software developer iCAD and image processing specialist TeraRecon have signed a nonexclusive product licensing and distribution agreement under which TeraRecon will develop a new server-based product offering to include iCAD lung cancer detection, analysis, and tracking software. Product release is expected in 2005. The stand-alone server product will work in concert with existing PACS and DICOM review equipment, as well as other products in the TeraRecon Aquarius product line. The three-year agreement provides for worldwide distribution through TeraRecon's direct sales force, independent resellers/distributors, and OEM partnerships. The companies have agreed to work together to obtain the FDA approvals necessary for U.S. distribution.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.